MAPT and Alzheimer disease: Specifically, we investigated whether these biomarkers for T (tau pathology) and N (neurodegeneration) within the ATN framework of AD pathology [6] and their changes over time could serve as molecular evidence for SCD as a distinct stage in the progression of AD.